C3L-00568
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 74.68309377
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- HEDGEHOG_SIGNALING+0.410
- MTORC1_SIGNALING+0.400
- E2F_TARGETS+0.380
- CHOLESTEROL_HOMEOSTASIS+0.330
- G2M_CHECKPOINT+0.330
- HYPOXIA+0.330
- WNT_BETA_CATENIN_SIGNALING+0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
- MYC_TARGETS_V1+0.260
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.490
- INTERFERON_GAMMA_RESPONSE-0.230
- ESTROGEN_RESPONSE_EARLY-0.220
- PANCREAS_BETA_CELLS-0.210
- PEROXISOME-0.140
- ADIPOGENESIS-0.130
- BILE_ACID_METABOLISM-0.080
- NOTCH_SIGNALING-0.080
- DNA_REPAIR-0.060
- ESTROGEN_RESPONSE_LATE-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02168 | — | cohortSQ2 | 0.775 |
| 2 | TCGA-E2-A1B0-01A-11R-A12P-07 | — | C | 0.741 |
| 3 | TCGA-34-5236-01A-21R-1820-07 | — | cohortSQ1 | 0.738 |
| 4 | TCGA-E2-A1LL-01A-11R-A144-07 | — | C | 0.736 |
| 5 | C3L-02130 | — | cohortSQ1 | 0.736 |
| 6 | MBCProject_2290_T2_RNA | — | E | 0.731 |
| 7 | TCGA-O2-A52V-01A-31R-A262-07 | — | cohortSQ1 | 0.728 |
| 8 | MNG1272 | — | — | 0.726 |
| 9 | MNG1297 | — | — | 0.725 |
| 10 | C3N-01028 | — | cohortSQ1 | 0.723 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.120 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |